Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Achillion nets $41.7mm via RDO

Executive Summary

Infectious disease-focused Achillion Pharmaceuticals Inc. has netted $41.7mm through the sale of 6.4mm common shares at $6.57 (market average) to funds managed by QVT Financial LP. The money will support ongoing development of its lead hepatitis C candidates sovaprevir (ACH1625; Phase II), ACH2684 (Phase I), and ACH3102 (Phase I).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies